Skip to content
Clinical Trials – home
Not yet recruiting

Study on Newborn Brain Conditions Using Sulfur Hexafluoride Ultrasound for Babies with Hypoxic-Ischemic Injury, Stroke, or Infections

Registered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on newborn babies with certain brain conditions. The study is looking at diseases that affect the brain's blood flow, such as hypoxic-ischemic brain injury, which occurs when the brain doesn't get enough oxygen, and brain infections. It also includes babies who have had a stroke or other brain issues like bleeding in the brain or hydrocephalus, which is a condition where fluid builds up in the brain. The trial will use a special imaging technique called contrast-enhanced ultrasound to see how well blood is flowing in the brain and how elastic the brain tissue is. The contrast used in this study is called SonoVue, which contains a substance known as sulfur hexafluoride.

The purpose of the study is to understand how these brain conditions affect blood flow and tissue elasticity in newborns during their first days of life. The study will involve giving the babies an injection of the contrast agent and then using ultrasound to take images of their brains. This will help doctors see how the blood is moving through the brain and how the brain tissue responds. The study will include babies who are full-term, those who have experienced a lack of oxygen at birth, those who have had a stroke, and those born prematurely.

Throughout the study, the babies will be monitored closely, and the imaging will be done in a safe and controlled environment. The study aims to gather important information that could help improve the understanding and treatment of these serious brain conditions in newborns. The trial will last for a period of up to 14 days for each baby, and the results will help doctors learn more about how these conditions affect the brain and how treatments can be improved in the future.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the newborn will be admitted to the neonatal intensive care unit. This is a specialized area in the hospital where babies who need extra care are monitored closely.

  2. Step 2

    Initial assessment

    The medical team will perform an initial assessment to understand the baby's current health status. This includes checking vital signs and ensuring the baby meets the study's inclusion criteria.

  3. Step 3

    Insertion of intravenous cannula

    An intravenous cannula, a small tube, will be placed in the baby's vein. This is necessary for administering the study medication and for any required blood tests.

  4. Step 4

    Administration of study medication

    The study involves the use of a medication called SonoVue, which contains sulfur hexafluoride. This medication is given as an intravenous bolus, meaning it is injected directly into the vein in a single dose. The purpose of this medication is to enhance ultrasound images of the brain.

  5. Step 5

    Ultrasound and elastography

    After the medication is administered, an ultrasound and elastography of the brain will be performed. These are imaging techniques used to assess the brain's blood flow and elasticity.

  6. Step 6

    Monitoring and follow-up

    The baby will be monitored closely for any changes in health status. Follow-up assessments will be conducted to gather data on how the treatment affects brain perfusion and elasticity.

  7. Step 7

    Completion of study participation

    Once all necessary data is collected, the baby's participation in the study will be complete. The medical team will ensure that the baby is stable and provide any necessary care before discharge from the study.

Who can join the trial?

12 criteria

  • Babies born between 37 weeks and 42 weeks of pregnancy who are in the newborn intensive care unit and have a small tube (called a cannula) placed in a vein for medical reasons.
  • Babies with an Apgar score of 8 or more at one and five minutes after birth. The Apgar score is a quick test done on a baby at 1 and 5 minutes after birth to see how well the baby is doing outside the mother's womb.
  • Babies with a blood pH value greater than 7.15. pH is a measure of how acidic or basic the blood is.
  • Babies with a birth weight between -2 and +2 standard deviations, meaning their weight is within a normal range for their age.
  • The mother did not have diabetes requiring medication during pregnancy.
  • No known brain disease or brain infection at birth or at the time of the study.
  • Babies suffering from hypoxic-ischemic brain injury or asphyxia, which are conditions related to a lack of oxygen.
  • Babies who have started cooling treatment or meet the criteria for cooling treatment due to asphyxia, even if the treatment has not started.
  • Babies who do not meet the cooling treatment criteria but have an Apgar score of 7 or less at 1 minute after birth and a blood pH of less than 7.10.
  • Babies diagnosed with a brain infarction, which is a type of stroke.
  • Premature babies born before 37 weeks of pregnancy who are scheduled for a brain MRI around their due date. An MRI is a type of scan that uses magnets and radio waves to take pictures of the inside of the body.
  • Babies with other brain conditions like brain infections, brain bleeding, or hydrocephalus, which is a condition where there is too much fluid in the brain.

Who cannot join the trial?

7 criteria

  • Patients with severe congenital malformations (serious birth defects) that affect the brain.
  • Patients with genetic disorders known to affect brain development.
  • Patients with severe infections that are not related to the brain.
  • Patients who have had major surgery within the first days of life.
  • Patients with unstable vital signs (such as heart rate, breathing, or blood pressure) that cannot be controlled.
  • Patients who are not expected to survive beyond the first week of life.
  • Patients whose parents or guardians do not give permission for participation in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

The provided data does not include specific medications or therapies involved in the clinical trial. The trial focuses on using contrast-enhanced ultrasound and elastography to study the brain in newborns, but no medications are mentioned. If you have more detailed information about the medications or therapies used in this trial, please provide it so I can assist you further.

What is already known about the treatment

I'm sorry, but the provided data does not include specific information about any medication involved in the clinical trial. Please provide the trade name or details of the medication for a detailed description.

Investigated diseases

  • Neonatal Hypoxic-Ischemic Encephalopathy

    This condition occurs when a newborn's brain does not receive enough oxygen and blood. It can happen during birth or shortly after. The lack of oxygen can cause brain cells to become damaged or die. Initially, the baby may appear lethargic, have difficulty breathing, or show abnormal reflexes. Over time, the brain may swell, leading to further complications. The progression can vary, with some infants showing improvement while others may develop long-term neurological issues.

  • Neonatal Stroke

    This condition involves a disruption of blood flow to a part of a newborn's brain, leading to brain cell damage. It can occur due to a clot or bleeding in the brain. Symptoms may include seizures, difficulty feeding, or reduced movement on one side of the body. As the condition progresses, some infants may develop motor or cognitive challenges. The extent of these challenges can vary widely. Early intervention can help manage some of the developmental issues.

  • Neonatal Central Nervous System Infections

    These infections affect the brain and spinal cord of newborns. They can be caused by bacteria, viruses, or other pathogens. Symptoms may include fever, irritability, poor feeding, or seizures. As the infection progresses, it can lead to inflammation and damage to brain tissues. The severity and outcomes depend on the type of infection and the timeliness of intervention. Long-term effects can include developmental delays or neurological deficits.

  • Former Preterm Infants at Term

    These are infants born prematurely but assessed at their expected full-term date. They may have experienced complications due to early birth, affecting their development. Initially, they might have difficulties with feeding, breathing, or maintaining body temperature. Over time, they may face challenges in growth and neurological development. Monitoring and support are crucial to address any emerging issues. The progression varies, with some infants catching up to their peers while others may need ongoing support.

  • Other Neonatal Brain Pathologies

    This category includes various conditions affecting the newborn brain, not limited to specific diseases. These can involve structural abnormalities, metabolic disorders, or other unspecified issues. Symptoms and progression depend on the specific pathology. Some conditions may present with seizures, developmental delays, or feeding difficulties. The impact on the infant's development can vary widely. Early detection and management are important to address potential complications.

Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2024-519611-33-00Protocol codeTL16102021Estimated enrolment200 patientsSponsorVarsinais-Suomen hyvinvointialue

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).